6972-05-0Relevant articles and documents
Convenient synthesis of 2,3-dihydro-1,2,4-thiadiazoles, 4,5-dihydro-1,3-thiazoles, and 1,3-thiazoles through a [4+1]-type oxidative ring closure of 1,3-thiaza-1,3-butadienes
Shimada, Kazuaki,Isogami, Megumi,Maeda, Kitami,Nishinomiya, Rei,Korenaga, Toshinobu
, p. 881 - 900 (2020/09/09)
1,3-Thiaza-1,3-butadienes bearing an N,N-dimethylamino group at the C-2 position were efficiently converted into 5H-1,2,4-oxathiazoles, 2,3-dihydro-1,2,4-thiadiazoles, 4,5-dihydro-1,3-thiazoles, and 1,3-thiazoles through an oxidative ring closure by treating with mCPBA, chloramine-T, metal carbenoids, or dichlorocarbene, respectively, via the ring closure of in situ generated heterocumulene-type reactive species involving thione S-oxides, thione S-imides, and thiocarbonyl ylides.
Sultam thioureas: Synthesis and antiviral activity against west nile virus
Feeny, Rachel M.,Le, Diane N.,Parks, Joseph W.,Epstein, Mark G.,Pagano, Joseph V.,Abbene, Albert C.,Graham, Elaina B.,Farrell, Joanna R.,McGuire, Jason R.,Zoellner, Robert W.,Valente, Edward J.,Barklis, Eric,Wood, Warren J. L.
supporting information; experimental part, p. 301 - 305 (2012/03/08)
The syntheses of eleven sultam thioureas, including nine new compounds, are described. These compounds were synthesized from thioureas and include the first sultam thioureas in which the two thiourea nitrogen groups are not identical. In addition, the first X-ray crystal structures of sultam thioureas and the antiviral activity of these compounds against West Nile virus (WNV) are reported. Georg Thieme Verlag Stuttgart New York.
THIAZOLE AND OXAZOLE KINASE INHIBITORS
-
Page/Page column 134, (2009/04/25)
The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
THIAZOLE AND OXAZOLE KINASE INHIBITORS
-
Page/Page column 147, (2009/07/17)
The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
Macrocylic Inhibitors of Hepatitis C Virus
-
Page/Page column 51, (2009/05/28)
Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(═O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl;R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl;p is independently 1 or 2;n is 3, 4, 5 or 6; — denotes an optional double bond;L is N or CRz; Rz is H or forms a double bond with the asterisked carbon;Rq is H or when L is CRz, Rq can also be C1-C6alkyl;Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl;R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl;R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV
Macrocyclic Inhibitors of Hepatitis C Virus
-
Page/Page column 59, (2009/02/11)
Compounds of the formula (I): and N-oxides, salts and stereoisomers thereof wherein A is OR1, NHS(═O)pR2, NHR3, NRaRb, C(═O)NHR3 or C(═O)NRaRb wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl or NRaRb; R3 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl, —OC1-C6alkyl, —OC0-C3alkylenecarbocyclyl, —OC0-C3alkyleneheterocyclyl; wherein any alkyl, carbocyclyl or heterocycylyl in R1, R2 or R3 are optionally substituted p is independently 1 or 2; n is 3, 4, 5 or 6; denotes an optional double bond; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Ry and Ry′ are independently C1-C6alkyl; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; W is —CH2—, —O—, —OC(═O)NH—, —OC(═O)—, —S—, —NH—, —NRa, —NHS(═O)2—, —NHC(=0)NH— or —NHC(═O)—, —NHC(═S)NH— or a bond; R8 is an optionally substituted ring system containing 1 or 2 saturated, partially saturated or unsaturated carbo or heterocyclic rings have utility in the inhibition of NS-3 serine proteases, such as flavivirus infections.
Synthesis and cytotoxicity studies of thiazole analogs of the anticancer marine alkaloid dendrodoine
Reji, T. F. Abbs Fen,Devi,Thomas,Sreejalekshmi,Manju,Francis,Philip,Bharathan,Rajasekharan
, p. 1145 - 1150 (2008/12/23)
The synthesis and cytotoxicity evaluation of 2-N,N-dimethylamino-5-indol-3- oylthiazole as the first member of a new portfolio of the thiazole analogs of the cytotoxic marine alkaloid dendrodoine (3-N,N-dimethylamino-5-indol-3-oyl-1, 2,4-thiadiazole) is described. Exploiting the opportunity arising from the replacement of the thiadiazole ring of dendrodoine by a thiazole ring which allowed further substitution on the five-membered ring, 2-N,N-dimethylamino-5- indoI-3-oyl-4-phenylthiazole has also been synthesized. Structural diversity is further extended by synthesizing 5-fur-2-oyl- and 5-coumarin-3-oyl-2-N,N- dimethylaminothiazoles, as well as 5-fur-2-oyl, 5-thiophen-2-oyl, 5-(1-methylbenzimidazol-2-oyl) and 5-benzothiazol-2-oyl derivatives of 2-N,N-dimethylamino-4-phenylthiazoles. Among these new N,N- dimethylaminothiazoles, 2-N,N-dimethylamino-5-indol-3-oyl-4-phenylthiazole shows significant in vitro cytotoxicity against a panel of human cancer cell lines.
HCV NS-3 serine protease inhibitors
-
, (2008/06/13)
HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, having the formula I wherein A is
HCV NS-3 serine protease inhibitors
-
, (2008/06/13)
HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, of formula: wherein A is
